Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Colestipol May Quickly Eliminate Teriflunomide
Patient reported outcome measures in neurogenic bladder.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Good Early Results for HERV Suppressor in MS
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
First proof for rituximab in IgG4-related disease
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
New approaches in the management of multiple sclerosis.
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Company restores access to multiple sclerosis drug after pressure from neurologists.
A genome-wide association study of brain lesion distribution in multiple sclerosis.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Differential roles of microglia and monocytes in the inflamed central nervous system.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
ALSUntangled No. 8: Low dose naltrexone for ALS.
The two faces of neuromyelitis optica.
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Application of fullerenes in nanomedicine: an update.

Pages